Diplomat Pharmacy (DPLO) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Leerink Partners Cuts Price target on Diplomat Pharmacy (DPLO) Following Weak EPS Guide
March 1, 2016 7:23 AM ESTLeerink Partners maintained an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $35.00 (from $40.00), following the company's 4Q. DPLO reported revenue of $987M, ahead of consensus' $970M. Adjusted EPS of $0.21 beat the consensus of $0.20. 2016 guidance calls for total revenue of... More
